Facebook
Twitter
LinkedIn
Forward
Thyroid Eye Disease: Management Across the Spectrum of Severity and Chronicity (CME Symposium)
To claim your credit for the symposium, please click Register/Take Course.
Target Audience
This educational activity is intended for ophthalmologists.
Learning Objectives
After completing this activity, participants will be better able to:
- Identify patients with thyroid eye disease who would be optimal candidates for treatment with biologic therapies
- Apply evidence to manage thyroid eye disease in patients with chronic disease
Faculty
 | Wendy W. Lee, MD, MS (Chair) Professor of Clinical Ophthalmology and Dermatology Oculofacial Plastic & Reconstructive Surgery, Orbit, and Oncology Bascom Palmer Eye Institute University of Miami Miller School of Medicine Miami, Florida |
 | Roger A. Dailey, MD |
 | Andrew R. Harrison, MD Professor Department of Ophthalmology and Visual Neurosciences Professor Department of Otolaryngology, Head and Neck Surgery Director, Ophthalmic Plastic and Reconstructive Surgery Service Co-Director, Center for Thyroid Eye Disease University of Minnesota Minneapolis, Minnesota |
 | Sonalika Khachikian, MD |
Disclosure Policy
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
Faculty
Roger A. Dailey, MD, is a consultant for Horizon Therapeutics plc and Viridian Therapeutics, Inc.
Andrew R. Harrison, MD, is a consultant for Horizon Therapeutics plc and RVL Pharmaceuticals, Inc; and is on the speakers bureau for Horizon Therapeutics plc and RVL Pharmaceuticals, Inc.
Sonalika Khachikian, MD, is a consultant for Horizon Therapeutics plc; is on the speakers bureau for Horizon Therapeutics plc; and is on the advisory board of Novo Nordisk A/S*.
Wendy W. Lee, MD, MS, is a consultant for Allergan, Horizon Therapeutics plc, Mallinckrodt*, Revance Therapeutics, Inc, RVL Pharmaceuticals, Inc, and Tarsus Pharmaceuticals, Inc.
* The financial relationship existed during the past 24 months but has now ended.
Peer Reviewer
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners, Managers, and Writers
Carrie Allen, PharmD, BCPP, BCPS, MedEdicus Content Manager for this activity, was previously employed by CVS within the past 2 years, but that relationship has ended.
Other MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.
Accreditation Statement
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from Horizon Therapeutics USA, Inc.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Horizon Therapeutics USA, Inc.
©2023 MedEdicus LLC. 304.1
Available Credit
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Participation